UCB's Global Corporate Website

EU study shows UCB’s investment in R&D

Posted by
Xavier Hormaechea, Public Affairs
Good news to start the year: the latest EU Industrial R&D Investment Scoreboard reveals UCB’s strong commitment to innovation, ranking the company as the number 1 R&D investor in Belgium.

With €780 million invested worldwide in R&D in 2011, UCB topped the table of Belgian companies investing in research and development. In fact, our company was the number 7 R&D investor in the EU pharma sector which comprises 104 companies.

Looking right across all sectors, from electronics to telecommunications and from medical devices to energy, UCB is the number 41 R&D investor of the top 1,000 EU companies included in the study.

Of the top 50 investors, UCB is ranked number 1 in terms of R&D investment per employee, highlighting the significant commitment of the company to investing in its pipeline of future medicines.

For us at UCB, the EU Scoreboard confirms what we already know: our company is a major investor in its own future – but it’s still great to see UCB’s R&D investment publicly recognised in an independent report by the European Commission.

Read the full study here or contact us if you have any questions.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.


Enter the characters shown in the image.